- voted against the re-election of four members of the incumbent Board, namely Messrs. Weidong Yin, Kenneth Lee, Meng Mei, and Simon Anderson;
- elected four new individuals to its Board of Directors, namely Messrs. Guowei Wang, Hoi Fung Qiu, Jianzeng Cao, and Pengfei Li, effectively immediately; and
- re-elected Mr. Yuk Lam Lo to its Board of Directors.
The announcement of the purported re-election of all directors dated March 5, 2018, was not authorized.On March 5, 2018, at the direction of the Former Directors, an announcement was made stating that, among other things, the Company had determined, after consultation with Antigua legal counsel, that a ballot proposed by certain shareholders at the Shareholders Meeting was invalid and therefore, all five of Sinovac's incumbent directors were re-elected by a majority of the votes validly casted. In addition, the announcement stated that two lawsuits had been filed on behalf of the Company in connection with the election of directors at the Shareholders Meeting. We hereby declare that the March 5, 2018 announcement was not authorized by the Current Board elected by shareholders on Feb 6 th, 2018, and, therefore, has no legal effect and should not be released to mislead the public and Sinovac's shareholders. The Former Directors did NOT have authorization to initiate two frivolous claims against its shareholders We understand that on March 5, 2018, the Former Directors caused the Company to file two lawsuits in connection with the election of directors at the Shareholders Meeting, one of which was filed in the Delaware Court of Chancery seeking a determination by the Court whether certain shareholders triggered the Company's shareholder rights plan, and the other was filed in the United States District Court of Massachusetts alleging that certain shareholders failed to make required disclosures in accordance with Section 13(d) of the Securities Exchange Act of 1934. We hereby declare that the Former Directors were NOT authorized to initiate the above two lawsuits against Sinovac's shareholders. The Current Board is considering all options and legal remedies available to it in response to the above unauthorized and unlawful actions.
Mr. Weidong Yin has been removed as the CEO of the Company due to his bribery conductsAccording to two written judgements issued by the Beijing No.1 Intermediate People's Court in late 2016 and early 2017, respectively, Mr. Weidong Yin as the general manager of Sinovac Biotech Co., Ltd., Sinovac's principal operating entity, bribed Mr. Hongzhang Yin, the then-vice director of the Center for Drug Evaluation of the China Food and Drug AdministrationIn consideration of the above judgments, the Current Board believes that Mr. Yin is not qualified to serve as the CEO of the Company, and therefore the Current Board has removed him from his position, effective immediately. The Current Board hereby declare that any action taken by the Former Directors concerning the operation and corporate governance of Sinovac is unlawful, has no legal effect, and against the best interests of the Company's shareholders. No person or group shall take actions on behalf of Sinovac without the approval and authorization of the Current Board. View original content: http://www.prnewswire.com/news-releases/sinovac-newly-elected-board-of-directors-response-to-the-announcement-of-the-purported-re-election-of-all-directors-at-the-february-6-2018-annual-general-meeting-300613831.html SOURCE Sinovac Biotech Ltd.